N/A N=8 Diagnostic

Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis

Eosinophilic Esophagitis

Bottom Line

View on ClinicalTrials.gov: NCT02227836 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2019

Primary outcome: Primary: Sensitivity of Patch Testing — 1 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Allergy Patch Testing (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Mayo Clinic
Primary completion: Sep 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Sensitivity of Patch Testing	1	—

Summary

This study is being done to see if allergy patch testing (APT) can help predict effective dietary therapy in patients with eosinophilic esophagitis.

Eligibility Criteria

Inclusion criteria

Adults ages 18-90
Patients with EoE, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field (eos per HPF) on index esophageal biopsy
Persistent symptoms and/or greater than or equal to 10 eos per HPF on esophageal biopsy after at least 8 weeks of twice daily PPI therapy

Exclusion criteria

Patients with conditions known to be associated with esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome
Topical swallowed steroids within 8 weeks of study enrollment
Dermatologic conditions precluding application of Finn chambers to the skin for APT
Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02227836). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.